Keyword: Jounce Therapeutics
The changes cut Celgene’s ties to ICOS and PD-1 programs that overlap with those in Bristol-Myers Squibb’s pipeline and portfolio.
Jounce shares fall after publication of an ASCO abstract giving initial data from a trial of its first-in-class ICOS inhibitor JTX-2011.
After a tough few months, sources are telling the Financial Times that Celgene is looking to buy out some biotech names with ties to the company.
Constellation raised $100 million that will bankroll a cancer epigenetics asset through the clinic.
UCSF scientist Shaun Coughlin will lead CV research at NIBR, Novo's China GM was promoted to EVP, and Cavion poached Teva exec to head up R&D.
Tocagen has filed to raise up to $86 million in an IPO to take its brain cancer gene therapy combination through the first part of a phase 2/3 trial.
Jounce Therapeutics has upsized its IPO and beaten the anticipated price range, bumping up its final haul to $104 million.
Six months after nabbing a potential $2.6 billion deal with Celgene, early-stage biotech Jounce has filed for a $75 million IPO that could serve as a broader litmus test for public offerings at the start of 2017.
Celgene highlighted a handful of immuno-oncology deals that are driving its long-term R&D prospects including Juno and bluebird CAR-T partnerships.